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Aberrant levels of preadipocyte differentiation, triggered by adipocyte hyperplasia and hypertrophy, results in the obesogenic phenotype. Obesity is a risk factor for several metabolic disorders. In this paper, dehydroleucodine inhibited the accumulation of lipid droplets and decreased the elevations of triglycerides, and this inhibitory effect occurred during the early stage of adipogenesis. Thus, not only did dehydroleucodine downregulate the expression of C/EBPα and PPARγ, it also strongly blocked the expression of C/EBPβ, an early stage biomarker of early adipogenesis, in a concentration-dependent manner. The proliferation of preadipocytes was dramatically suppressed when dehydroleucodine was added to the medium as early as 24 hr. These results indicate that dehydroleucodine may specifically affect mitotic clonal expansion to inhibit preadipocyte differentiation. Dehydroleucodine arrested the cell cycle at the G 0 /G 1 phase, increased p27 and decreased both cyclins A and D and their partners (e.g., CDK2 and CDK4). Additionally, dehydroleucodine decreased phosphorylation of Erk1/2 and Akt. Furthermore, dehydroleucodine downregulated expression of histone demethylase JMJD2B as well as repressed the expression of histone methyltransferase MLL4, which in turn diminished the expression of C/EBPβ and PPARγ, respectively. Collectively, our results indicate that dehydroleucodine inhibits preadipocyte differentiation by blocking mitotic clonal expansion via cell cycle arrest, which may be mediated by regulation of selective histone methylation/demethylation in transcription activation during the early step of adipogenesis.
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| INTRODUCTION
Ours is the first generation in the 200,000-year history of Homo sapiens where more members of our species are overweight and obese than underweight (Di Cesare et al., 2016) . This sudden rise in global obesity prevalence from 105 million individuals in 1975 to 641 million in 2014 (Di Cesare et al., 2016) has coincided with a rise in a plethora of obesity related pathologies including cardiovascular disease (Florido et al., 2017) , diabetes mellitus (Al-Goblan, Al-Alfi, & Khan, 2014) , cancer (Zheng et al., 2017) , stroke (R. Chen, Yan, Liu, Wang, & Wang, 2017) , vascular dementia (Ilenia, Daniele, Michele, Enea, & Tayebati, 2017), and Alzheimer's disease (Ilenia et al., 2017) . Although obesity is most commonly defined as a body mass index or BMI (body mass divided by the square of the body height) of over 30 kg/m 2 , it is fundamentally characterized by an aberrant and excessive accumulation of adipose tissue due to adipocyte hyperplasia and hypertrophy (Muir et al., 2016) .
These adipogenic processes can be modeled in vitro by utilizing a 3T3-L1 murine preadipocyte model system (Ruiz-Ojeda, Ruperez, Gomez-Llorente, Gil, & Aguilera, 2016) , where cells are differentiated into mature adipocytes over the course of approximately 9 days through stimulation with an induction media (IM) cocktail consisting of growth media (GM) with dexamethasone, isobutylmethylxanthin (IBMX), and insulin, in the first phase of differentiation, and GM with insulin alone in the second phase of differentiation. The transition to a mature adipogenic phenotype is evidenced by the accumulation of triglycerides (Rosen & Spiegelman, 2000) , as well as the expression and/or phosphorylation of numerous genes including Akt1, Erk1/2, (Moon et al., 2007) , the transcriptional factor peroxisome proliferator-activated receptor γ (PPARγ), and CCAAT/enhancerbinding proteins (C/EBPs). C/EBPβ is expressed within 2 to 4 hr of treatment with IM and crucially acquires DNA binding activity at 12 hr post induction, which coincides with the essential process of mitotic clonal expansion (MCE).
In this process cells undergo growth arrest followed by two to four rounds of mitosis, which is a necessary phase for the progression and completion of the adipocyte differentiation program (Tang, Otto, & Lane, 2003) . C/EBPβ's DNA binding functionality is aided by retinoblastoma protein (Rb; P. L. Chen, Riley, Chen, & Lee, 1996) . In contrast to Rb's role in negatively regulating transcription factor E2F-1 to prevent quiescent cells from passing a restriction point in G1, Rb binds with and activates C/EBPβ and does so specifically during the adipogenic differentiation process (P. L. Chen et al., 1996) . MCE also requires a synchronized activation of the ERK and p38 signaling pathways (Aouadi et al., 2007; Tang et al., 2003) . Progression from G1 to S requires downregulation of p27 and activation of CDK2 by cyclins E and A (Patel & Lane, 2000) . Cyclin D1 and cyclin E are activated during the G 1 phase of the cell cycle (Choi et al., 2012) . Once activated, cyclin D1 assembles with CDK4 or CDK6, or both, and cyclin E binds to CDK2 (Choi et al., 2012) . Cyclins A and B are then recruited to CDK2 and CDK1, respectively, associations necessary for the inducement of cell cycle progression through S phase and mitosis (Choi et al., 2012) . Activated C/EBPβ, along with C/EBPδ, triggers the expression of C/EBPα, which leads to the expression of PPARγ (Farmer, 2006) . Once C/EBPβ is activated during MCE, it targets the promoter of the chromatin regulator gene Kdm4b, whereas C/EBPβ as a cofactor targets the promoters of cell cycle genes, including Cdc45l (cell division cycle 45 homolog) demethylates H3K9me3 in their regulatory regions, which in turn activates their transcription (Guo et al., 2012) . Cdc451 is a component of the CMG (CDC451 (protein), MCM (minichromosome maintenance), GINS (Sld5, Psf1, Psf2, and Psf3.)) complex, which is required for the initiation and elongation steps of eukaryotic chromosomal DNA replication (Tercero, Labib, & Diffley, 2000) . Histone demethylase CDC25A is required for progression from G1 to the S phase of the cell cycle and acts by activating the pro-mitotic Cdc2 (CDK1) and also by activating G1/S cyclin-dependent kinases CDK4 and CDK2 by removing inhibitory phosphate groups from adjacent tyrosine and threonine residues (Goloudina et al., 2003) . C/EBPβ also stimulates expression of histone H3K9 demethylase JMJD2B, which removes H3K9me3 and H3K9me2 on the promoters of PPARγ and C/EBPα, which stimulates their expression (Guo et al., 2012; Jang, Kim, & Jung, 2017) . MLL3 and MLL4, H3K4me1/2 methyltransferases that become part of the activating signal cointegrator-2-containing complex (ASCOM), both redundantly coactivate PPARγ and C/EBPα (Lee et al., 2008) . In opposition to these effects, histone methyltransferase G9a represses PPARγ expression by adding H3K9me2 to the entire PPARγ gene locus and promotes Wnt10a expression independent of its methyltransferase activity, therefore repressing adipogenesis (Wang et al., 2013) .
Dehydroleucodine (DhL), a sesquiterpene lactone of the guaianolide group, which contains an α-methylene-γ-lactone ring, has been isolated from the aerial parts of Artemisia douglasiana (Giordano et al., 1990) . Although DhL significantly inhibited the differentiation of 3T3-L1 preadipocytes in a time and concentration dependent manner by blocking the expression of PPARγ and C/EBPα (Galvis et al., 2011) , the exact cellular and molecular mechanism by which DhL affected differentiation of 3T3-L1 preadipocytes is still not well understood. Interestingly, DhL inhibited proliferation and altered the cell cycle of cancer cells (Costantino et al., 2013) . Therefore, it is possible that DhL affects the early stage of the differentiation of 3T3-L1 preadipocytes (i.e., MCE). The objective of this paper was to explore the effect of DhL on MCE during differentiation of 3T3-L1 preadipocytes, as well as elucidate aspects of the mechanism by which these effects occur. Aridas, Mendoza, Argentina) as previously described (Giordano et al., 1990 
| Cell viability assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) (Thermo Fisher Scientific. Inc., Pittsburgh, PA) colorimetric assay was utilized to quantify cellular viability. Cells (1 × 10 6 cells/ml) were incubated at 37°C and 5% CO 2 in the absence or presence of different concentrations of DhL for various periods of time. After this initial incubation, cells were treated with MTT reagent at a final concentration of 5 mg/ml in phosphate buffer saline (PBS), and further incubated at 37°C and 5% CO 2 . Next, the formazan crystals were dissolved in a detergent reagent, and each condition was then quantified via spectrophotometry (Ultrospec 2100 Pro UV/Visible Spectrophotometer)
at an optical density of 570 nm (OD 570 ) as described early (Barbieri, Fernandez-Pol, Hunker, Horazdovsky, & Stahl, 2004) .
| Oil Red O Staining, microscopy, and spectrophotometry
After the 3T3-L1 preadipocytes were transferred from T75 flasks (where they were grown to approximately 80% confluence) to 12 well plates, GM was replaced with IM, and the cells underwent treatment 
| Triglyceride assay
The lipid droplets in the cellular suspension were analyzed for total concentration of triglyceride as previously described (Mendez, Cabeza, & Hsia, 1986) . Briefly, preadipocytes undergoing differentiation upon application of IM were treated with different concentrations of DhL for Days 0-2 and 0-8. Cells were washed with PBS, scraped, centrifuged, and lysed with 1% Triton X-100. Cell lysates were then centrifuged at 10,000× g for 20 min at 4°C. Then, cell supernatants were used to measure the conversion of triglycerides to fatty acids and glycerol. DMSO was used as a vehicle control. The supernatants were then oxidized and quantified at OD 540 based on a triglyceride standard curve (Cayman Chemical, Arbor, MI).
| Cell proliferation assay
3T3-L1 cells (5 × 10 4 cells/ml) were cultured in appropriate plates and then incubated with GM. When 3T3-L1 cells reached confluence, cells
were incubated with IM in the absence or in the presence of various concentrations of DhL for 24 and 48 hr. DMSO was utilized as a vehicle control and preadipoyctes incubated in the absence of IM was used as a negative control. Cells were then harvested and quantified using an automated cell counter machine from Bio-Rad (Hercules, CA).
| Western blot analysis
After postconfluent preadipocytes were cultured in the absence or presence of IM and treated with 9-μM DhL for 10 min, 3 hr, or 24 hr, cell lystate preparation was conducted via the washing of cell monolayers with a mixture of ice-cold lysis buffer (20-mM Tris-HCL pH 7.5, 150-mM NaCl, 1% NP40, 1-mM Na 2 EDTA, and 0.1% Na Deoxycholate), protease inhibitors, and phosphatase inhibitors. After centrifugation, protein concentrations were quantified through the use of the BCA protein assay. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Thermo Fisher Scientific.
Inc., Pittsburgh, PA), blocked in 5% bovine serum albumin overnight at 4°C, and probed with the appropriate primary antibodies for 2 hr at room temperature. Membranes were next incubated with horseradish peroxidase-conjugated secondary antibodies overnight at 4°C.
Bands were visualized with enhanced chemiluminescence, and the intensities of the bands were quantified in WCIF Image J for Windows (University Health Network Research, Toronto, Canada), and relative levels of proteins were determined by densitometry analysis. as follows: It started by the denaturation cycle at 95°C for 30 min, and it was followed by incubation at 95°C 10 min, and at 60°C for 25 min, respectively. The mRNA expression was normalized to GAPDH.
| Flow cytometry analysis
Relative gene expression was expressed as fold change in mRNA expression level compared with control.
| High-performance liquid chromatography
The SpectraSystem SMC1000 solvent delivery system, vacuum membrane degasser, P4000 gradient pumps, and AS3000 autosampler (Thermo Electro Corporation, San Jose, CA) were utilized for highperformance liquid chromatograhy. Column effluent was monitored at 254 nm (OD 254 ) with Spectra System UV6000LP variable wavelength PDA detector and ChromQuest 4.1 software. DhL was separated using a C18 YMC column, purified and identified as previously described (Galvis et al., 2011; Penissi, Piezzi, Villar, & Rudolph, 2003) .
| Statistical analysis
All experiments were independently performed in triplicate. The standard error of the mean of triplicates was utilized and significance was analyzed by one-way ANOVA or Student's Test. All statistical data were from averages of the three independent experiments.
Results with *p < .01 and ** p < .001 were considered statistically significant. All values are presented as the mean ± SEM of three independent experiments performed in triplicate. *p < .01 versus no DhL treatment. (f and g) Cells were incubated with DhL and harvested, and the lysates were subjected to Western blot analysis for PPARγ, C/EBPα, and C/EBPβ. GAPDH was used as a loading control. The Western blots were performed three times, and a representative image of the three independent experiments was shown for days 4-6 (16 ± 2% of inhibition), whereas the treatment for days 6-8 showed no inhibition at all. As expected, the addition of DhL on 3T3-L1 preadipocytes undergo MCE through the upregulation of C/EBPβ and C/EBPδ during the early stage of adipocyte differentiation. This is followed by the activation of the downstream signaling molecules PPARγ and C/EBPα, which are critical for terminal adipocyte differentiation (Farmer, 2005) . Therefore, we examined the effect of DhL on the expression of C/BEPβ, during the first 48 hr after stimulation of 3T3-L1 preadipocytes with IM. Expression of C/BEPβ was significantly decreased in a concentration-dependent manner when cells were treated with DhL ( Figure 1d ). In addition, PPARγ and C/EBPα expression in adipocytes treated with DhL strongly decreased compared with the control cells ( Figure 1f ). This was further evidenced in multiple experiments including the Oil Red O assays where both lipid droplet number and size were quantified after treatment with DhL. In these assays, both number of lipid droplets and size were reduced under all treatment conditions ( Figure S1A ).
| DhL inhibits MCE through downregulation of cyclins A and D and cyclin-dependent kinases 2 and 4
C/BEPβ, a specific transcriptional factor expressed in the early stage of adipogenesis, is also known to be required for MCE. Consequently, we determined whether DhL affects proliferation of 3T3-L1 preadipocytes after induction of differentiation with IM. As shown in Figure The number of cells treated with different concentrations of DhL for 24 and 48 hr was determined using an automated cell counter machine. DMSO was used a vehicle control, and preadipocytes incubated in the absence of differentiation medium was used a negative control. All values are presented as the mean ± SEM of three independent experiments performed in triplicate. *p < .01, **p < .001 versus no DhL treatment. (b) After treatment of preadipocytes with 9-μM DhL for 24 hr, stained with a propidium iodide solution, and the cell population was analyzed by flow cytometry as described in Section 2. The percentage of cell population at each stage of the cell cycle was determined using Accuri C6 software. (c-h) After treatment of preadipocytes with 9-μM DhL for 24 hr, cells were harvested and the lysates were subjected to Western blot analysis for (c) Cyclin A, (d) Cyclin D1, (e) CDK2, (f) CDK4, and (g) p27. Western blot analysis for GAPDH was used as loading control.
(h) Pre-adipocytes treated with 9-μM DhL for 10 min or 3 hr were harvested, and the lysates were subjected to Western blot analysis for total (t)-Erk1/2, t-Akt, phospho(p)-Erk1/2 and p-Akt. The Western blots were performed three times, and a representative image of the three independent experiments was shown effects of DhL that cause inhibition of proliferation of 3T3-L1 preadipocytes appear to occur during the early stage of adipogenesis.
We then investigated whether DhL modulates cell cycle progres- To determine the signaling pathway through which DhL inhibited the clonal expansion during the early stage of adipogenesis, the expression and phosphorylation of Erk1/2 and Akt, which are involved in cell cycle progression, were examined. Adipogenic inducers increased the phosphorylation of Erk1/2 and Akt (Figure 2h ). When the adipocytes were treated with 9-μM DhL for 10 min or 3 hr, both
Erk1/2 and Akt phosphorylation was significantly decreased, but not to the level demonstrated for cyclin protein abundance.
| DhL blocks expression of C/EBPβ and PPARγ MCE
Several histone methyltransferases and demethylases have been reported to be involved in adipogenesis. These enzymes seem to regulate expression of C/EBPβ and PPARγ (Guo et al., 2012; Lee et al., 2008) . To further assess the regulators involved in the DhL inhibition of MCE, we examined the expression of C/EBPβ in DhL-treated 3T3-L1 cells at the indicated time after IM induction as indicated in Figure 3 . Level of expression of mRNA C/EBPβ was increased in the presence of IM treatment during the 18 hr. However, the addition of DhL clearly diminished the C/EBPβ mRNA level (Figure 3a) , which expression has been correlated with the regulation of H3K9 demethylase JMJD2B and cell cycle genes (e.g., Cdc25c; Guo et al., 2012) . Interestingly, protein expression of C/EBPβ was also decreased ( Figure S2A ). Thus, we determined the expression of JMJD2B and the cell cycle genes in DhL-treated 3T3-L1 cells during the MCE process.
We observed that the JMJD2B mRNA level was also reduced by DhL treatment (Figure 3b ). Interestingly, we also observed a dramatic inhibition of the expression of mRNA levels of cell cycle genes Cdc25A and Cdc451 during MCE (Figure 3c,d) . and oxidization (Cordell, 1976) .
In Figure S4A , the pH of solution has a dramatic effect on DhL stability in liquid state. DhL is comparatively stable when the environmental pH is in the range of 5 to 7, becoming unstable when pH is less than 3 or more than 7.
In Figure S4B , DhL (in solid stage) content remains constant for 40-day storage in a refrigerator (4°C). At 25 and 37°C, DhL begins to degrade slowly after 30 days. We only observed 3 ± 2% and 5 ± 1% degradation, respectively. However, DhL degradation can reach 17 ± 5% after 40-day storage at 50°C.
The bioavailability and uptake of DhL were determined using
Caco-2 as well as in 3T3-L1 cells as essentially described early (Walle, Galijatovic, & Walle, 1999) . In Caco-2 cells, the permeability coefficient and percent transport of DhL at a concentration of 200 μM were determined in the apical part of the monolayer.
Transport of DhL was observed with permeability coefficient value of 10.06 × 10 −6 cm/s and a percent transport of 26.31 ± 0.71%. The cumulative amount transported was linear with time, and it was monitored for a period of 3 hr. Moreover, in 3T3-L1 cells, the cumulative amount transported was also linear with time ( Figure S4C ).
| DISCUSSION
Approximately 50% of modern pharmaceuticals derived from traditional plant compounds (Bilia et al., 2017) . C/EBPβ is expressed within 2 to 4 hr post induction (Tang et al., 2003) , and we observed in this study that 3 and 6 μM of DhL led to a drastic downregulation of protein levels of C/EBPβ ( Figure 1d ). As the acquisition of DNA binding activity of C/EBPβ beginning at approximately 12 hr post induction is essentially required for the progression of MCE (Tang et al., 2003) , this represents strong evidence that DhL inhibits adipogenesis by obstructing the MCE process. As activated C/EBPβ, along with C/EBPδ, triggers the expression of C/EBPα, which leads to the expression of PPARγ (Farmer, 2006) , the inhibitory effects of DhL on C/EBPβ would be expected to result in a downreguation of protein levels of PPARγ and C/EBPα. This is precisely what was observed when increasing concentrations of DhL (at 3, 6, 12 μM, and beyond) was applied in our study, which drastically downregulated and Akt, as well as via its upregulation of p27.
DhL also repressed the expression of CDC25A, CDC451, and JMJD2B (Figure 3) , which all act downstream of C/EBPβ to facilitate progression through the cell cycle (Aressy & Ducommun, 2008; Guo et al., 2012; Turowski et al., 2003) . mRNA levels of the H3K4me1/2 methyltransferase MLL4 were downregulated upon application of DhL (Figure 4c ), and PPARγ mRNA was also downregulated, as would be expected from the literature reporting that MLL4 is part of the ASCOM, which coactivates PPARγ (Lee et al., 2008) . No significant effects were found on mRNA levels upon application of DhL for the expression of MLL3 (Figure 4b ), also a part of the ASCOM (Lee et al., 2008) , or the expression of G9A (Figure 4d ), which represses PPARγ expression (Wang et al., 2013) .
It is plausible that this multitude of effects, which arrest the necessary step of MCE, stem from the upstream inhibitory effect DhL may have on C/EBPβ function. Alternatively, DhL could also affect factors necessary to express C/EBPβ or activate C/EBPβ's DNA binding activity. Such targets could possibly include Rb, which DhL decreased phosphorylation of Rb in this study (Barbieri, M. A., personal communication October 23, 2017) , and which binds to C/EBPβ and facilitates its activation (P. L. Chen et al., 1996) . It is also possible that DhL acts redundantly and directly on numerous processes downstream of C/EBPβ activation, such as obstructing MLL4, which was downregulated in this study (Figure 4c ). MLL3 and MLL4 are part of the ASCOM, which are integral to the activation of PPARγ and C/EBPα (Lee et al., 2008) . DhL could possibly exert its antiadipogenic effects by acting upon C/EBPβ rather than the ASCOM. In a similar fashion, DhL may act directly on the epigenetic modifiers as shown in this study, which include CDC25A, CDC45l, and JMJD2B (Figure 3b-d) . Further studies can better clarify these mechanistic issues where DhL could be considered as an agent with either a more generic or specific antiadipogenic activity.
We also examined the stability, absorption, and bioavailability of the DhL in our study. Clearly, the stability of DhL is affected in different environment aqueous solution, suggesting that hydrolysis may be the predominant degradation pathway of DhL solution that is subject to specific-acid and specific-base catalyzers. In solid, state of DhL (i.e., dry powder), which contained very limited amount of water, makes its degradation highly unlikely even at temperature more than 37°C for the period of time examined. Interestingly, the data on permeability of DhL can be compared with a representative model compound (i.e., propranolol) for absorption. Propranolol is a cellular transport marker, which is highly lipophilic, and exhibits a high value of permeability coefficient (i.e., 14.8 × 10-6 ; Chong, Dando, & Morrison, 1997) . The permeability coefficient value of DhL observed in our study is lower than that of propranolol but higher than parthenolide (Khan, Abourashed, Khan, & Walker, 2003) ; hence, DhL could be in the category of moderate to high absorption.
To further characterize the potential efficacy of DhL, preliminary pharmacologic studies were indicate that an i.p. DhL dose of 50 mg/ kg reached a concentration maximum (C max ) of 12.7 μM and a half-life (T 1/2 ) of 47 min in serum. In addition, oral bioavailability was approximately 66% compared with i.p. administration. Furthermore, in preliminary toxicology studies, daily administration of 50 mg/kg DhL to mice for 5 consecutive days was well tolerated (Barbieri, M. A., manuscript in preparation), which is consistent with previous observations that DhL is well tolerated in rodents (Costantino et al., 2016; Penissi, Giordano, Guzmán, Rudolphd, & Piezzi, 2006) .
This study has elucidated some of the early mechanistic effects of DhL-facilitated adipogenic inhibition during the early stage process of MCE. We hope that it will lead to future studies to further investigate its antiadipogenic mechanism during MCE that may lead to translational efforts to ameliorate our current obesity situation.
